The 16 references in paper S. Rachina A., N. Dekhnich N., R. Kozlov S., A. Bobylev A., G. Batishcheva A., S. Gordeeva A., Yu. Kulakov V., M. Lebedeva S., U. Portnyagina S., I. Zakharenkov A., С. Рачина А., Н. Дехнич Н., Р. Козлов С., А. Бобылев А., Г. Батищева А., С. Гордеева А., Ю. Кулаков В., М. Лебедева С., У. Портнягина С., И. Захаренков А. (2016) “ОЦЕНКА ТЯЖЕСТИ ВНЕБОЛЬНИЧНОЙ ПНЕВМОНИИ В РЕАЛЬНОЙ КЛИНИЧЕСКОЙ ПРАКТИКЕ В МНОГОПРОФИЛЬНЫХ СТАЦИОНАРАХ РОССИЙСКОЙ ФЕДЕРАЦИИ // SEVERITY ASSESSMENT OF COMMUNITY9ACQUIRED PNEUMONIA IN REAL CLINICAL PRACTICE IN A MULTI9PROFILE HOSPITAL IN RUSSIA” / spz:neicon:pulmonology:y:2016:i:5:p:521-528

1
Инфекционная заболеваемость в Российской Федерации. Доступно на http:// www.rospotrebnadzor.ru
(check this in PDF content)
2
Заболеваемость населения России. Федеральное государственное бюджетное учреждение «Центральный научно-исследовательский институт организации и информатизации здравоохранения» Министерства здравоохранения и социального развития Российской Федерации. Доступно наhttp:// www.mednet.ru
(check this in PDF content)
3
The global burden of disease: 2014 update. World Health Organization.Available from http:// www.who.int
(check this in PDF content)
4
Гельфанд Б.Р., Салтанов А.И., ред. Интенсивная терапия: национальное руководство. М.: ГЭОТАР-Медиа; 2011. Т. 2.
(check this in PDF content)
5
Menéndez R., Reyes S., Martínez R. et al. Economic evaluation of adherence to treatment guidelines in nonintensive care pneumonia. Eur. Respir. J. 2007; 29 (4): 751–756.
(check this in PDF content)
6
Meehan T., Weingarten S., Holmboe E. et al. A statewide initiative to improve the care of hospitalized pneumonia patients: The Connecticut Pneumonia Pathway Project. Am. J. Med. 2001; 111: 203–210.
(check this in PDF content)
7
Benenson R., Magalski A., Cavanaugh S., Williams E. Effects of a pneumonia clinical pathway on time to antibiotic treatment, length of stay, and mortality. Acad. Emerg. Med.1999; 6: 1243–1248.
(check this in PDF content)
8
Fine M.J., Auble T.E., Yealy D.M. et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N. Engl. J. Med. 1997; 336: 243–250.
(check this in PDF content)
9
Lim W.S., van der Eerden M.M., Laing R. et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003; 58: 377–382.
(check this in PDF content)
10
Чучалин А.Г., Синопальников А.И., Козлов Р.С. и др. Клинические рекомендации по диагностике, лечению и профилактике тяжелой внебольничной пневмонии у взрослых. Consilium Medicum. 2015; 17 (3): 8–37.
(check this in PDF content)
11
Macfarlane J., Rose D. Radiographic features of staphylococcal pneumonia in adults and children. Thorax. 1996; 51: 539–540.
(check this in PDF content)
12
Charles P.G.P., Wolfe R., Whitby M. et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin. Infect. Dis.2008; 47: 375–384.
(check this in PDF content)
13
Dellinger R.P., Levy M.M., Rhodes A. et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012.Crit. Care Med. 2013; 41 (2): 580–637.
(check this in PDF content)
14
Chalmers J.D., Singanayagam A., Hill A.T. C-reactive protein is an independent predictor of severity in communityacquired pneumonia. Am. J. Med.2008; 121: 219–225.
(check this in PDF content)
15
Nseir W., Farah R., Mograbi J. et al. Impact of serum C-reactive protein measurements in the first 2 days on the 30-day mortality in hospitalized patients with severe community-acquired pneumonia: A cohort study. J. Crit. Care. 2013; 28 (3): 291–295.
(check this in PDF content)
16
Zhydkov A., Christ-Crain M., Thomann R. et al. Utility of procalcitonin, C-reactive protein and white blood cells alone and in combination for the prediction of clinical outcomes in community-acquired pneumonia. Clin. Chem. Lab. Med.2015; 53 (4): 559–566.
(check this in PDF content)